top of page
Smiling Senior Couple
iStock-498833660.jpg

Get In Touch

We'd love to hear from you.

LENZ®:
Late-stage Clinical Therapy in Hematology/Oncology and  Serious Inflammatory Conditions

Lenzilumab (LENZ) is a first-in-class monoclonal antibody which neutralizes a growth factor (GM-CSF) implicated in certain types of leukemia and serious inflammatory conditions. LENZ is currently being studies in a Phase 2/3 trial in Australia in newly-diagnosed patients with with Chronic MyeloMonocytic Leukemia (CMML).

The existing Standard of Care shows efficacy in the 7-21% range according to extensive published data. By adding LENZ to one of the Standards of Care, the efficacy rate has so far climbed to more than 80%. Further, more than 80% of patients retain benefit for more than a year and some patients have received benefit (to date) for more than 4 years. Typically, patients would have a much shorter life-span.

LENZ has been shown in this and many other disease states to be safe and well-tolerated. The findings have been presented at prestigious oral presentations at the American Society of Hematology medical conference in San Diego in December 2024 and the European Hematology Association medical conference in Milan in June 2025.

An international confirmatory Phase 3 study that could encompass US, Australian, UK and European sites is planned in CMML. Early data points to the possibility of LENZ providing potential benefit in AML, MDS, autoinflammation, CHIP and oncology treatment-associated myeloid neoplasms, all conditions where LENZ has demonstrated encouraging either in vitro or clinical data sufficient to merit further investigation. LENZ has a robust and comprehensive Chemistry, Manufacturing, and Controls (CMC) package.


A Phase 3 study protocol has been signed off by FDA using LENZ as a companion therapy to CAR-T therapy in cancer and focused on minimizing or eradicating serious and potentially life-threatening side-effects of the CAR-T therapy while also potentially increasing the effectiveness of the CAR-T therapy. A leading US-based (and internationally recognized) expert hospital network has agreed to lead this Phase 3 study which may lead to an approval for LENZ in this use.​

IFAB is a first-in-class monoclonal antibody engineered to target a receptor called EphA3  found in breast, lung, pancreas, brain, colon, kidney and certain other cancers, but not found in normal cells. A published Phase 1 study in the brain cancer Glioblastoma Multiforme demonstrated that treatment was well tolerated, while IFAB showed rapid, specific targeting of the tumor.

 

The company has developed Antibody-Drug Conjugate (ADC) molecules based on IFAB and has pre-clinical animal PK data with the  optimized ADC constructs. We are preparing to study these ADCs in a Phase 1 'basket' study across a range of solid tumor types.

 

In addition, a Phase 2 study was completed in myelofibrosis and AML, with some positive findings and has been published.  ​

TRN005 is a first-in-class anti-eosinophil antibody engineered for potential effectiveness against a variety of inflammatory diseases. High blood counts of eosinophils (a type of white blood cell) are associated with rare conditions such as eosinophilic leukemia, Churg-Strauss syndrome (also known as eosinophilic granulomatosis with polyangiitis), certain forms of asthma and COPD, rhinosinusitis with nasal polyps, various gastro-intestinal diseases, including certain food allergies, colitis, and inflammatory bowel disease.

Taran is seeking to divest TRN005 to a company able to leverage its promise.​

bottom of page